The pivotal study by Hegi et al. (2005) (7), conducted within the landmark EORTC–NCIC phase III trial comparing radiotherapy alone to radiotherapy with TMZ (the Stupp protocol), established MGMT promoter methylation as both a prognostic and predictive biomarker in glioblastoma. Here, MGMT is linked to glioblastoma.